Skip to main content
Journal ArticleOPEN ACCESS

Ocrelizumab for relapsing or primary progressive MS

  • Chaplin S
Prescriber (2018) 29(9) 35-37
DOI: 10.1002/psb.1705
N/ACitations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Ocrelizumab (Ocrevus) is a new monoclonal antibody treatment for patients with relapsing‐remitting multiple sclerosis (RRMS) and for those with early primary progressive multiple sclerosis (PPMS). This article summarises its indications, efficacy and adverse effects.

Cite

CITATION STYLE

APA

Chaplin, S. (2018). Ocrelizumab for relapsing or primary progressive MS. Prescriber, 29(9), 35–37. https://doi.org/10.1002/psb.1705

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free